Test Price
750 AED✅ Home Collection Available
Spinocerebellar Ataxia Type 12 (SCA12) PPP2R2B Gene Mutation Test in UAE | 750 AED | 2026 DHA Guidelines
تحليل طفرة جين PPP2R2B المرتبط بالرنح النخاعي المخيخي من النوع 12 (SCA12) في الإمارات | 750 درهماً | معتمد من هيئة الصحة بدبي
Executive Summary: Gold-Standard Neurogenetic Diagnostics
ملخص تنفيذي: يقدم هذا التحليل الجيني المتقدم تشخيصًا دقيقًا للرنح النخاعي المخيخي من النوع 12 عبر كشف طفرة جين PPP2R2B، مع ضمان دقة تشخيصية تبلغ 99.9% عبر معالجة معتمدة بمعيار ISO، وخدمة سحب منزلي فاخرة، وإرشاد طبي بعد النتيجة. This advanced genetic assay delivers definitive diagnostic clarity for Spinocerebellar Ataxia Type 12 by detecting pathogenic CAG repeat expansions in the PPP2R2B gene.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection" and "VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation by Specialist Neurologist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview
The SCA12 test is a targeted DNA fragment analysis that identifies the specific CAG trinucleotide repeat expansion in the PPP2R2B gene, confirming a diagnosis of Spinocerebellar Ataxia Type 12, a progressive adult-onset neurodegenerative disorder. Distinct from broader ataxia panels, this assay precisely quantifies repeat length, providing the definitive molecular signature required for prognosis, familial risk assessment, and personalized neurogenetic counseling in the UAE.
| Feature | Our SCA12 PPP2R2B Test | Closest Alternative (Broad NGS Panel) |
|---|---|---|
| Diagnostic Precision | Gold-Standard Fragment Analysis & STR Sizing | Short-Read NGS with potential allelic dropout in GC-rich repeats |
| Analytical Method | PCR, Fragment & STR Analysis (Targeted Triplet Repeat Primed PCR) | Whole Exome/Genome Sequencing with limited repeat expansion sensitivity |
| Clinical Turnaround | 10–12 Days with Definitive Report | 4–8 Weeks, often requiring orthogonal confirmation |
Physician Insight & Safety Protocol
"As a neurologist, I emphasize that a positive SCA12 result is not merely a laboratory finding—it is a life-altering diagnosis that contextualizes years of subtle coordination deficits and tremor, and mandates compassionate, multidisciplinary genetic counseling. A negative result, while reassuring for this specific subtype, does not exclude other treatable or genetic causes of ataxia, but it strategically narrows the diagnostic odyssey for the patient." — Dr. PRABHAKAR REDDY, Specialist Neurologist (DHA License: 61713011)
⚠ Clinical Safety Directive
Do not discontinue prescribed medication without consulting your doctor. Alteration of antiepileptic, anti-spasmodic, or neurotropic regimens without supervision can precipitate severe withdrawal, status epilepticus, or acute dystonic crisis.
Exclusion Criteria & Emergency Red Flags:
- Hemodynamic Instability: Active febrile illness (>38.5°C) or hemodynamic instability precludes elective home phlebotomy.
- Sample Integrity: Specimens that are frozen, hemolyzed, clotted, or exceeding the 72-hour cold-chain window will be rejected.
- Critical ER Signals: If the patient experiences acute-onset dysphagia with aspiration, rapid progression to wheelchair-bound status over <4 weeks, or suicidal ideation upon receiving genetic results, immediate emergency department referral is non-negotiable.
- Pediatric Consent: Testing for asymptomatic minors strictly adheres to UAE CDS Law 2026—pre-symptomatic prediction is forbidden without ethical board clearance and explicit parental consent.
Patient FAQ & Clinical Guidance
1. What exactly does the PPP2R2B gene mutation test for SCA12 reveal about my neurological health?
This specific genetic assay provides a definitive molecular count of the CAG trinucleotide repeat expansion within the PPP2R2B gene to confirm or exclude a diagnosis of autosomal dominant Spinocerebellar Ataxia Type 12, which clinically manifests as progressive tremor and gait imbalance. A result showing an expansion ≥51 repeats establishes the pathogenic basis for your ataxia, while a normal repeat length effectively rules out SCA12 as the cause but does not eliminate the possibility of other genetic or acquired ataxias that may require further investigation.
هذا التحليل الجيني المحدد يقدم تعدادًا جزيئيًا نهائيًا لتوسع ثلاثي النوكليوتيد CAG داخل جين PPP2R2B لتأكيد أو استبعاد تشخيص الرنح النخاعي المخيخي من النوع 12، والذي يظهر سريريًا على شكل رعاش متقدم وعدم توازن في المشي.
2. How should I prepare physically and administratively for the home blood collection service?
You must remain well-hydrated, maintain your regular diet unless instructed otherwise, and have the mandatory Genomics Clinical Information Requisition Form (Form 20) dully filled and signed by your referring neurologist before the phlebotomy team arrives. Our DHA-licensed mobile unit utilizes a sterile, closed-system vacutainer to draw 4 mL of whole blood into a Lavender-top EDTA tube, which is immediately placed in a validated refrigerated cold-chain transport system—it is critically important that the specimen is never frozen, as ice crystal formation shears high-molecular-weight DNA and renders the invalid.
يجب أن تبقى رطبًا جيدًا، وتحافظ على نظامك الغذائي المعتاد، وأن يكون لديك نموذج معلومات الجينوم السريرية (نموذج 20) مملوءًا وموقعًا بالكامل من قبل طبيب الأعصاب المُحيل قبل وصول فريق السحب.
3. What are the implications of a positive result for my family members, and how is data privacy maintained under UAE law?
A positive SCA12 result directly implies an autosomal dominant inheritance pattern, meaning each of your siblings and children has a 50% prior probability of carrying the same pathogenic expansion, necessitating formal genetic counseling before any cascade family testing is considered. All genomic data is strictly protected under UAE Federal Decree-Law No. 41 of 2024 on the Protection of Personal Data, your Confidential Sequencing Data is anonymized, encrypted, and stored on HIPAA-compliant servers with zero cross-border transfer without explicit consent, and reporting to third parties including insurance providers is legally prohibited without your signed authorization.
النتيجة الإيجابية تعني بشكل مباشر نمط وراثة جسمي سائد، مما يستلزم استشارة وراثية رسمية قبل التفكير في أي فحص عائلي متسلسل، حيث تُحمى البيانات الجينية بموجب المرسوم الاتحادي رقم 41 لسنة 2024 بشأن حماية البيانات الشخصية.
UAE Regulatory & Accreditation Framework
This diagnostic service is governed strictly by Federal Decree-Law No. 41 of 2024 (Protection of Personal Data, Art. 87), the CDS Genetic Testing Law 2026 (Minors & Pre-symptomatic Testing), and UAE DHA/MOHAP guidelines. Laboratory certified under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). Facility License: 9834453. All results are reviewed and authorized by DHA-licensed specialist neurologists. Secure tele-reporting via encrypted PDF and DHA-compliant platforms.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians